Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07224763 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Safety and Efficacy of the GGTA1 KO Thymokidney in Patients With ESRD
A Phase 1 study of Kidney Transplantation and ESRD (End-Stage Renal Disease), sponsored by United Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT07224763 is a Phase 1 study of Kidney Transplantation and ESRD (End-Stage Renal Disease) that is actively recruiting participants, run by United Therapeutics. The registered enrollment target is 50 participants, below the 266-participant average among 33 other Kidney Transplantation trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07224763, a Phase 1 study of Kidney Transplantation and ESRD (End-Stage Renal Disease), is actively recruiting participants, sponsored by United Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the safety and efficacy of the GGTA1 KO Thymokidney in patients with end-stage renal disease (ESRD) who are either not eligible for conventional allogeneic kidney transplantation (Group 1) or are on an Organ Procurement and Transplantation Network (OPTN) kidney transplant waitlist, but are more likely to die or go untransplanted within 5 years than receive a kidney transplant (Group 2). The study consists of xenotransplantation followed by a 24-week Post-transplant Follow-up Period (Part A) to evaluate the efficacy and safety objectives followed by a Long-term Follow-up Period (Part B) to evaluate participant survival, GGTA1 KO Thymokidney survival, and screening for zoonotic infections. Part B will continue for the lifetime of the participant or for 52 weeks following nephrectomy, if required.
Conditions Studied
Interventions
- BIOLOGICAL GGTA1 KO Thymokidney
Study Locations (1)
New York
- New York University Langone Health - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2026-03 |
| Est. Completion | 2076-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07224763
The ClinicalTrials.gov registry entry for NCT07224763 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 266-participant average among 33 other Kidney Transplantation trials with a reported enrollment target (81% lower). The listed sponsor is United Therapeutics, which has 63 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Kidney Transplantation appearing as the primary indexed condition, and to 1 intervention - of which GGTA1 KO Thymokidney is the first listed.
NCT07224763 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT07224763 about?
NCT07224763 is a clinical study titled "Study to Evaluate the Safety and Efficacy of the GGTA1 KO Thymokidney in Patients With ESRD". The purpose of this study is to evaluate the safety and efficacy of the GGTA1 KO Thymokidney in patients with end-stage renal disease (ESRD) who are either not eligible for conventional allogeneic kidney transplantation (Group 1) or are on an Organ Procurement and Transplantation Network (OPTN) kidn...
What is the current status of trial NCT07224763?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2026-03. Estimated completion is 2076-03.
What conditions does trial NCT07224763 study?
This clinical trial studies the following conditions: Kidney Transplantation, ESRD (End-Stage Renal Disease), Xenotransplantation.
What interventions are being tested in trial NCT07224763?
The interventions under investigation include: GGTA1 KO Thymokidney (BIOLOGICAL).
Who is sponsoring clinical trial NCT07224763?
This trial is sponsored by United Therapeutics, which has 63 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07224763 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Transplantation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate the Safety and Efficacy of the 10 GE Xenokidney in Patients With ESRD
RECRUITING · Phase 1
-
Tolerance by Engaging Antigen During Cellular Homeostasis
COMPLETED · Phase 1
-
CCFZ533X2201 - PoC Study in de Novo Renal Transplantation
COMPLETED · Phase 1
-
Combination Immunosuppressive Therapy to Prevent Kidney Transplant Rejection in Adults
COMPLETED · Phase 1
-
Reduced Immunosuppression in Older Renal Transplant Recipients With Trugraf®/TRAC Monitoring (RIOT Trial): A Prospective, Randomized, Multicenter Trial.
RECRUITING · Phase 4
-
Shared Decision Making for Kidney Transplant Candidates to Plan for an Organ Offer Decision
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.